An Audit of the Use of Cabazitaxel for the Treatment of Metastatic Castrate Resistant Prostate Cancer (mCRPC) Compared with Previous Experience with ECarboF (Epirubicin, Carboplatin and 5-fluorouracil) in a Single Institution. Issue 5 (May 2016)